Comanche Biopharma

Executive Summary

Comanche Biopharma is a private biopharmaceutical company developing CBP-101, a novel siRNA therapy targeting sFLT1 for the treatment of preterm preeclampsia, a leading cause of maternal and fetal morbidity. Founded in 2020 and headquartered in Concord, Massachusetts, the company addresses a critical unmet need with a first-in-class approach to safely lower sFLT1 levels, potentially halting disease progression and allowing pregnancy to continue. Preclinical data have shown promising efficacy, and the company is advancing CBP-101 into clinical development. Its mission to provide evidence-based, affordable therapies aligns with a growing demand for targeted treatments in maternal health, positioning Comanche as a pioneer in a high-risk, high-reward therapeutic area.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical trial interim data readout60% success
• Q2 2026FDA clearance to initiate Phase 2 trial75% success
• TBDStrategic partnership or licensing agreement for ex-US rights30% success